NOV 15, 2018 09:00 AM PST

Comprehensive Genomic Profiling Becoming a New Standard-of-Care in Oncology

SPONSORED BY: Illumina
Speakers
  • Chief Medical Officer, Illumina, Inc.
    Biography
      For the past 25 years, Dr. Febbo has worked at leading institutions throughout the United States, most recently serving as CMO of Genomic Health (NASDAQ:GHDX). Prior to joining Genomic Health, Dr. Febbo served as Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. While at UCSF, Dr. Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology.

      Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College, received his M.D. degree at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. After his fellowship in medical oncology at the Dana-Farber Cancer Institute, he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). In 2004, Dr. Febbo moved to Duke University Medical Center's Institute of Genome Sciences and Policy. He has been a member of the American Society for Clinical Investigation since 2009.
    • Clinical Oncology Marketing, Illumina, Inc.
      Biography
        Maude is a specialist in molecular biology applications in oncology, across technologies and platforms. Her experience includes contributing to the FDA-approval of 5 Companion Diagnostic (CDx) molecular assays, creating the global go-to-market strategy for a dozen of CDx at various stages in regulatory approval. Maude has educated pathologists and oncologists in early adoption of technologies that have changed medicine and cancer treatments in the last decade.

      Abstract:

      The value behind a comprehensive assessment of the genomic alterations in a tumor has been consistently increasing with the availability of new therapeutic agents and better predictability of response. The regulatory and reimbursement for this type of assay evolved drastically over the last years. We will discuss how this change in environment provides strong value to adopt comprehensive genomic profiling in today's oncology care.


      Show Resources
      You May Also Like
      SEP 05, 2019 04:00 PM CEST
      C.E. CREDITS
      SEP 05, 2019 04:00 PM CEST
      DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
      OCT 02, 2019 11:00 AM PDT
      OCT 02, 2019 11:00 AM PDT
      DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
      AUG 27, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 27, 2019 09:00 AM PDT
      DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
      NOV 18, 2019 07:00 AM PST
      C.E. CREDITS
      NOV 18, 2019 07:00 AM PST
      DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
      JUL 30, 2019 10:00 AM PDT
      C.E. CREDITS
      JUL 30, 2019 10:00 AM PDT
      DATE: July 30, 2019TIME: 10:00am PT/ 1:00pm ET The importance of building a validation structure within your lab cannot be overstated. Once in place, the ability to identify high...
      AUG 14, 2019 09:00 AM PDT
      C.E. CREDITS
      AUG 14, 2019 09:00 AM PDT
      DATE: August 14, 2019TIME: 9:00am PT. 12:00pm ET Implementation of Lean Methodology in Biobanking Operations to standardize sample management processes is effective. Each proce...
      Loading Comments...
      Show Resources